Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).

about

Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain.

P2860

Q39007494-D7BD2E05-A8AC-4A26-9102-880B78954499

P2860

Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).

Item

http://www.wikidata.org/entity/Q38071643

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel prostaglandin receptor m ...... a patent review (2002 - 2012).

@en

type

Item

label

Novel prostaglandin receptor m ...... a patent review (2002 - 2012).

@en

prefLabel

Novel prostaglandin receptor m ...... a patent review (2002 - 2012).

@en

P1476

Novel prostaglandin receptor m ...... a patent review (2002 - 2012).

@en

P2093

Daniel Flesch

http://www.w3.org/2001/XMLSchema#string

P2860

Prostaglandins and inflammation.

International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress

The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache.

Targeting prostaglandin E EP receptors to inhibit metastasis.

BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.

Prostanoid receptors as possible targets for anti-allergic drugs: recent advances in prostanoids on allergy and immunology.

Roles of prostaglandin E2 in cardiovascular diseases.

COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention.

A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.

An improved synthesis of the selective EP4 receptor agonist ONO-4819.

P304

233-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543776.2013.744822

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Manfred Schubert-Zsilavecz

D Merk

Christina Lamers

P577

2013-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23289354

http://www.w3.org/2001/XMLSchema#string

Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).

about

P2860

P2860

Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698